{"id":"gemcitabine-cisplatine","safety":{"commonSideEffects":[{"rate":"40-80","effect":"Myelosuppression (neutropenia, thrombocytopenia)"},{"rate":"70-90","effect":"Nausea and vomiting"},{"rate":"20-40","effect":"Nephrotoxicity"},{"rate":"10-30","effect":"Ototoxicity"},{"rate":"10-20","effect":"Peripheral neuropathy"},{"rate":"30-50","effect":"Anemia"},{"rate":"20-40","effect":"Alopecia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Gemcitabine is a nucleoside analog that interferes with DNA synthesis by inhibiting ribonucleotide reductase and being incorporated into DNA, causing chain termination. Cisplatin is a platinum-based alkylating agent that forms covalent DNA adducts and crosslinks, preventing DNA unwinding and replication. Together, they provide complementary cytotoxic mechanisms targeting rapidly dividing cancer cells.","oneSentence":"Gemcitabine and cisplatin work synergistically as a chemotherapy combination, with gemcitabine inhibiting ribonucleotide reductase to disrupt DNA synthesis and cisplatin forming DNA crosslinks to prevent replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:13:54.132Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic non-small cell lung cancer"},{"name":"Urothelial carcinoma"},{"name":"Ovarian cancer"},{"name":"Pancreatic cancer"}]},"trialDetails":[{"nctId":"NCT07036380","phase":"PHASE2","title":"MP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract Carcinoma","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2025-12-22","conditions":"Advanced Biliary Tract Carcinoma","enrollment":75},{"nctId":"NCT01812369","phase":"PHASE3","title":"Perioperative Chemotherapy for Patients With Locally Advanced Bladder Cancer","status":"COMPLETED","sponsor":"University Hospital, Rouen","startDate":"2013-02","conditions":"Bladder Cancer","enrollment":500},{"nctId":"NCT07128290","phase":"PHASE2","title":"PErioperative CISGEM + Rilvegostomig in High-Risk Resectable Intra Hepatic CholangioCarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2025-10-30","conditions":"Intrahepatic Cholangiocarcinoma (Icc)","enrollment":49},{"nctId":"NCT06156514","phase":"PHASE3","title":"Evaluation of Concomitant Chemo-radiotherapy With Cisplatine vs Gemcitabin in Locally Advanced Cervicouterine Cancer","status":"RECRUITING","sponsor":"National Institute of Cancerología","startDate":"2019-11-06","conditions":"Locally Advanced Cervical Cancer, Gemcitabine, Chemo-radiotherapy","enrollment":140},{"nctId":"NCT06623162","phase":"PHASE2","title":"Sasanlimab As Maintenance Treatment Based on Clinical Response to Neoadjuvant Treatment in Molecularly Categorized Muscle Invasive Bladder Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Fundación de investigación HM","startDate":"2024-12","conditions":"Mibc, Muscle Invasive Bladder Cancer","enrollment":70},{"nctId":"NCT06531447","phase":"PHASE2","title":"First-line Gemcitabine Plus Cisplatin in Locally Advanced (IIIC Stage) Breast Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"The National Center of Oncology, Azerbaijan","startDate":"2014-05","conditions":"Breast Cancer","enrollment":200},{"nctId":"NCT03123445","phase":"PHASE2","title":"Endostar First-line Treatment of Advanced NSCLC","status":"UNKNOWN","sponsor":"China Medical University, China","startDate":"2017-04","conditions":"Non Small Cell Lung Cancer","enrollment":150},{"nctId":"NCT00416507","phase":"PHASE3","title":"Gemcitabine With or Without Combination Chemotherapy and Radiation Therapy in Treating Patients With Nonmetastatic Pancreatic Cancer That Cannot Be Removed By Surgery","status":"COMPLETED","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2000-03","conditions":"Pancreatic Cancer","enrollment":190},{"nctId":"NCT00198354","phase":"PHASE3","title":"Stage I/II NSCLC Perioperative Chemotherapy","status":"COMPLETED","sponsor":"Intergroupe Francophone de Cancerologie Thoracique","startDate":"2001-05","conditions":"Non-small Cell Lung Cancer Stage I and II, Peri-operative Chemotherapy","enrollment":530},{"nctId":"NCT00556621","phase":"PHASE1, PHASE2","title":"Gemcitabine, Cisplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Bladder Cancer","status":"COMPLETED","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","startDate":"2005-06","conditions":"Bladder Cancer","enrollment":14},{"nctId":"NCT00303758","phase":"PHASE3","title":"Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery","status":"COMPLETED","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2005-10","conditions":"Pancreatic Cancer","enrollment":202}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"GEMCITABINE CISPLATINE","genericName":"GEMCITABINE CISPLATINE","companyName":"University Hospital, Rouen","companyId":"university-hospital-rouen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Gemcitabine and cisplatin work synergistically as a chemotherapy combination, with gemcitabine inhibiting ribonucleotide reductase to disrupt DNA synthesis and cisplatin forming DNA crosslinks to prevent replication. Used for Advanced or metastatic non-small cell lung cancer, Urothelial carcinoma, Ovarian cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}